[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adrenocortical-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adrenocortical-carcinoma":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,92,117,139,170,209,243,265,292,314,334],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":69,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":91},"100289631","familial-investigations-of-childhood-cancer-predisposition-100289631",false,"NCT03050268","Familial Investigations of Childhood Cancer Predisposition","SJFAMILY","NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown below, you may enroll regardless of the results of your clinical genetic testing.\n\nDEFINITION OF FAMILIAR CANCER FOR THIS PROTOCOL:\n\nIn this protocol, the definition of \"Familial Cancer\" is met if any of the following is present:\n\n* An individual with a history of cancer diagnosed under 26 years of age who has at least one first, second or third degree relative with a history of cancer diagnosed under 51 years of age; OR\n* An individual who has been diagnosed with more than one cancer, at least one of which was diagnosed under 26 years of age; OR\n* An individual with a clinical or molecular diagnosis of a known cancer predisposition syndrome; OR\n* An individual with a congenital cancer diagnosed before 6 months of age; OR\n* An individual with a rare pediatric cancer or tumor diagnosed before 26 years of age\n\nº Excluding human papilloma virus-associated cervical cancer and non-melanoma skin cancer occurring in adults.\n\nINCLUSION CRITERIA:\n\n* An individual who meets this protocol's definition of \"Familial Cancer,\" as above.\n* Biologic relatives of an individual meeting this protocol's definition of \"Familial Cancer,\" who are either affected or unaffected by cancer.\n\nEXCLUSION CRITERIA:\n\n* An inability or unwillingness of the research participant or his\u002Fher legally authorized representative (LAR) to provide written informed consent.\n* The participant has received allogeneic bone marrow transplantation and has NO pre-transplant germline (cancer-unaffected) DNA available AND is unwilling to provide a skin sample.","ALL",{"count":18,"type":19},1500,"ESTIMATED","OBSERVATIONAL","NOTE: This is a research study and is not meant to be a substitute for clinical genetic testing. Families may never receive results from the study or may receive results many years from the time they enroll. If you are interested in clinical testing please consider seeing a local genetic counselor or other genetics professional. If you have already had clinical genetic testing and meet eligibility criteria for this study as shown in the Eligibility Section, you may enroll regardless of the results of your clinical genetic testing.\n\nWhile it is well recognized that hereditary factors contribute to the development of a subset of human cancers, the cause for many cancers remains unknown. The application of next generation sequencing (NGS) technologies has expanded knowledge in the field of hereditary cancer predisposition. Currently, more than 100 cancer predisposing genes have been identified, and it is now estimated that approximately 10% of all cancer patients have an underlying genetic predisposition.\n\nThe purpose of this protocol is to identify novel cancer predisposing genes and\u002For genetic variants. For this study, the investigators will establish a Data Registry linked to a Repository of biological samples. Health information, blood samples and occasionally leftover tumor samples will be collected from individuals with familial cancer. The investigators will use NGS approaches to find changes in genes that may be important in the development of familial cancer. The information gained from this study may provide new and better ways to diagnose and care for people with hereditary cancer.\n\nPRIMARY OBJECTIVE:\n\n* Establish a registry of families with clustering of cancer in which clinical data are linked to a repository of cryopreserved blood cells, germline DNA, and tumor tissues from the proband and other family members.\n\nSECONDARY OBJECTIVE:\n\n* Identify novel cancer predisposing genes and\u002For genetic variants in families with clustering of cancer for which the underlying genetic basis is unknown.",[23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68],"Acute Leukemia","Adenomatous Polyposis","Adrenocortical Carcinoma","AML","BAP1 Tumor Predisposition Syndrome","Carney Complex","Choroid Plexus Carcinoma","Constitutional Mismatch Repair Deficiency Syndrome","Diamond-Blackfan Anemia","DICER1 Syndrome","Dyskeratosis Congenita","Emberger Syndrome","Familial Acute Myeloid Leukemia","Familial Adenomatous Polyposis","Fanconi Anemia","Familial Cancer","Familial Wilms Tumor","Familial Neuroblastoma","GIST","Hereditary Breast and Ovarian Cancer","Hereditary Paraganglioma-Pheochromocytoma Syndrome","Hodgkin Lymphoma","Juvenile Polyposis","Li-Fraumeni Syndrome","Lynch Syndrome","MDS","Melanoma Syndrome","Multiple Endocrine Neoplasia Type 1","Multiple Endocrine Neoplasia Type 2","Neuroblastoma","Neurofibromatosis Type 1","Neurofibromatosis Type II","Nevoid Basal Cell Carcinoma Syndrome","Non Hodgkin Lymphoma","Noonan Syndrome and Other Rasopathy","Overgrowth Syndromes","Pancreatic Cancer","Peutz-Jeghers Syndrome","Pheochromocytoma\u002FParaganglioma","PTEN Hamartoma Tumor Syndrome","Retinoblastoma","Rhabdoid Tumor Predisposition Syndrome","Rhabdomyosarcoma","Rothmund-Thomson Syndrome","Tuberous Sclerosis","Von Hippel-Lindau Disease",[70,71,72,73,74,75,76,77,78],"Familial cancer","Genetic predisposition","Heritable disease","Cancer risk","Genome analysis","Genetic modifiers","Next generation sequencing (NGS)","Genetic counseling","DNA","RECRUITING","2026-06-15",{"date":82,"type":83},"2026-06-17","ACTUAL",{"date":85,"type":83},"2017-04-06",{"date":87,"type":19},"2037-03-31",{"name":89,"class":90},"St. Jude Children's Research Hospital","OTHER",1,{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":4,"eligibilityCriteria":98,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":99,"enrollmentInfo":100,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":102,"conditions":103,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":91},"100107943","adrenal-tumors---pathogenesis-and-therapy-100107943","NCT00669266","Adrenal Tumors - Pathogenesis and Therapy","Investigation of the Tumorigenesis of Adrenal Tumors and Evaluation of New Therapeutic Options - Untersuchungen Zur Tumorgenese Von Nebennierentumoren Und Evaluation Neuer Therapieoptionen","Inclusion Criteria:\n\n* adrenal tumor detected by imaging\n\nExclusion Criteria:","100 Years",{"count":101,"type":19},500,"The pathogenesis of adrenal tumors is still not fully elucidated and the treatment options for malignant tumors are poor. The current study investigates different aspects of the pathogenesis of adrenal tumors and evaluates different therapeutic options in patients with adrenocortical carcinoma.",[104,25,105,106,107],"Adrenal Tumors","Cushing Syndrome","Conn Syndrome","Pheochromocytoma","2026-05-01",{"date":110,"type":83},"2026-05-07",{"date":112,"type":83},"2002-09",{"date":114,"type":19},"2032-12",{"name":116,"class":90},"University of Wuerzburg",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":126,"conditions":127,"keywords":128,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":91},"100091717","german-adrenocortical-carcinoma-registry-100091717","NCT00453674","German Adrenocortical Carcinoma Registry","Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of adrenocortical carcinoma",{"count":125,"type":19},1000,"Basic objective of the German Adrenocortical Carcinoma Registry is to improve the care of patients with adrenocortical cancer. The registration of as many patients as possible helps to collect data for the prognosis and prospects of success regarding different treatment plans. This data will be taken into consideration for planning prospective studies. With this registry, the recruitment of patients for prospective studies will be significantly facilitated. In this way - and in cooperation with networks in other countries (e.g. in Italy and France) - a structure allowing systematic improvement of therapy will be developed.",[25],[129,130,131,132],"Adrenal cancer","Treatment","Surgery","Mitotane",{"date":110,"type":83},{"date":135,"type":83},"2003-01",{"date":137,"type":19},"2030-12",{"name":116,"class":90},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":149,"phases":150,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100521187","phase-2-study-of-radiotherapy-and-pembrolizumab-in-people-with-adrenocortical-carcinoma-100521187","NCT06066333","Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma","Safety and Immunological Effects of Pembrolizumab Plus Ablative Radiotherapy in Patients With Advanced Adrenocortical Carcinoma","Inclusion Criteria:\n\n* Be willing and able to provide written informed consent for the trial.\n* Be ≥ 15 years of age on day of signing informed consent.\n* Have histologically- or cytologically- confirmed metastatic ACC with symptomatic liver metastases.\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or\n* Adequate performance status:\n\n  1. Patients \\\u003C 16 years of age: Lansky ≥ 50%\n  2. Patients ≥ 16 years of age: Karnofsky ≥ 50%\n* Have measurable disease based on RECIST v1.1.\n* Have radiologic documentation of extrahepatic tumor, defined as extrahepatic metastases.\n* Consent for use of archived tissue for research purposes. Archival tissue (1 block or 20 unstained slides) will be requested, when available.\n* Demonstrate adequate organ function as defined in Table 1, all screening labs should be performed within 28 days of treatment initiation.\n\nTable 1: Adequate Organ Function Laboratory Value\n\nHematological Absolute neutrophil count (ANC) ≥1,500 \u002F mcL Platelets ≥100,000 \u002F mcL\n\nRenal Serum creatinine ≤1.5 X upper limit of normal (ULN) OR Measured or calculated creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≥60 mL\u002Fmin for subject with creatinine levels \\> 1.5 X institutional ULN\n\n\\*Creatinine clearance should be calculated per institutional standard.\n\nHepatic Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels \\> 1.5 ULN AST (SGOT) and ALT (SGPT) ≤ 5 X ULN\n\nCoagulation International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n\n* Female subjects of childbearing potential should have a negative serum pregnancy test within 72 hours prior to beginning treatment on study. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication (Reference Section 10.6.2). Subjects of childbearing potential are those who have not been surgically sterilized or have not been free of menses for \\>1 year.\n* Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n\nNote: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nExclusion Criteria:\n\n* Is currently participating in or has participated in a study of an investigational agent or using an investigational device within 4 weeks prior to study Day 1 (the first day of ablative RT).\n* Has undergone radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields (to include Y90).\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study Day 1. The use of physiologic doses of corticosteroids for adrenal and pituitary insufficiency is not considered a form of systemic steroid therapy and would not exclude a subject from the study.\n* Has had a prior monoclonal antibody within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier. The use of non-immunotherapy monoclonal antibodies (such as dupilumab (for eczema), omalizumab (for urticaria), benralizumab (for asthma)) would not exclude a subject from the study.\n* Has had prior chemotherapy, targeted small molecule therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent.\n\nNote: Subjects with ≤ Grade 2 neuropathy or ≤ Grade 2 alopecia are an exception to this criterion and may qualify for the study.\n\n* If subject underwent major surgery, they must have recovered adequately from the toxicity and\u002For complications from the intervention prior to starting therapy.\n* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative therapy.\n* Has known active central nervous system metastases and\u002For carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to beginning treatment on study and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for brain metastases for at least 7 days prior to study Day 1. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.\n* Has an active autoimmune disease requiring systemic treatment within the past 3 months or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents. Subjects with vitiligo or resolved childhood asthma\u002Fatopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study. Subjects that have adrenal or pituitary insufficiency that require physiologic corticosteroid replacement therapy would not be excluded from the study. Subjects who are on mitotane for control of hormonal symptoms for their disease at the time of eligibility assessment can continue on mitotane during the course of the study.\n* Has evidence of interstitial lung disease or history of (non-infectious) pneumonitis that required steroids or current pneumonitis. 11. Has an active infection requiring systemic therapy. 12. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator. 13. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 14. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1\u002F2 antibodies).\n* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Has received a live vaccine or live-attenuated vaccine within 30 days prior to study Day 1. Administration of killed vaccine is allowed.","18 Years",{"count":148,"type":19},12,"INTERVENTIONAL",[151],"PHASE2","The purpose of this study is to determine whether pembrolizumab given after standard ablative Radiotherapy is a safe treatment that causes few or mild side effects in people with advanced Adrenocortical Carcinoma.",[25,154,155],"ACC","Metastatic Adrenocortical Carcinoma",[25,154,155,157,158,159,160],"Metastatic ACC","Metastatic ACC with symptomatic liver metastases","23-272","Memorial Sloan Kettering Cancer Center","2026-04-14",{"date":163,"type":83},"2026-04-15",{"date":165,"type":83},"2023-09-27",{"date":167,"type":19},"2026-09-27",{"name":160,"class":90},7,{"id":171,"slug":172,"hasResults":11,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":177,"enrollmentInfo":178,"targetDuration":4,"studyType":149,"phases":180,"briefSummary":182,"conditions":183,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":208},"100371641","phase-1-gene-modified-immune-cells-after-conditioning-regimen-for-the-treatment-of-stage-iiic-or-iv-melanoma-or-metastatic-solid-tumors-100371641","NCT04119024","Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors","Phase I Dose Escalation Study of Systemically Administered IL13Ra2 Chimeric Antigen Receptor (CAR) T Cells After a Nonmyeloablative Conditioning Regimen in Patients With Metastatic Melanoma and Other Solid Tumors","Inclusion Criteria:\n\n* Histologically confirmed malignancy that is considered surgically incurable with either:\n\n  * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis\n  * Stage IV melanoma including patients with known brain metastases\n  * Other metastatic, non-central nervous system (CNS) solid tumor relapsed or refractory after all standard-of-care systemic therapies for which the patient is eligible\n* Confirmed IL13Ralpha2 tumor expression by immunohistochemistry (immunohistochemical assay \\[IHA\\] H-Score \\>= 50 in at least 10% of the total tumor specimen and in at least two high-power fields)\n* Age greater than or equal to 18 years old and less than 75 years old\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* A minimum of one measurable lesion defined as:\n\n  * Meeting the criteria for measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST), OR\n  * Skin lesion(s) selected as non-completely biopsied target lesion(s) that can be accurately measured and recorded by color photography with a ruler to document the size of the target lesion(s)\n* Absolute neutrophil count (ANC) \\>= 1 x 10\\^9 cells\u002FL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Platelets \\>= 75 x 10\\^9\u002FL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Hemoglobin \\>= 9.5 g\u002FdL (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Aspartate and alanine aminotransferases (AST, ALT) =\\\u003C 2.5 x upper limit of normal (ULN) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Total bilirubin =\\\u003C 2 x ULN (except patients with documented Gilbert's syndrome) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Creatinine \\\u003C 2 mg\u002FdL (or a glomerular filtration rate \\> 45) (determined within 30-60 days prior to enrollment; re-evaluated within 14 days of beginning conditioning chemotherapy)\n* Patients with melanoma must have progressed following \\>= 1 line of systemic therapy, including immune checkpoint inhibitor and a BRAF inhibitor in combination with MEK inhibitor for patients with BRAF V600-activating mutation and is not considered to have an alternate treatment option with curative intent\n* Must be willing and able to accept at least one leukapheresis procedure (This does not apply for patients receiving a second infusion of IL13R a2 CAR T cells as they will not undergo leukapheresis)\n* Must be willing and able to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to purify \\>= 1 x 10\\^7 T cells from leukapheresis product (this does not apply to patients receiving a second infusion of IL13Ra2 CAR T cells as they will not undergo leukapheresis)\n* Previously known hypersensitivity to any of the agents used in this study; known sensitivity to cyclophosphamide or fludarabine\n* Received systemic treatment for cancer, including immunotherapy, within 14 days prior to initiation of conditioning chemotherapy administration within this protocol\n* Clinically active brain metastases. Radiological documentation of absence of active brain metastases at screening is required for all patients. Prior evidence of brain metastasis successfully treated with surgery or radiation therapy will not be exclusion for participation as long as they are deemed under control at the time of study enrollment\n* Potential requirement for systemic corticosteroids or concurrent immunosuppressive drugs based on prior history or received systemic steroids within the last 2 weeks prior to enrollment; not including patients with primary or secondary adrenal insufficiency who require physiologic replacement with steroids, or patients on inhaled or topical steroids at standard doses\n* Human immunodeficiency virus (HIV) seropositivity or other congenital or acquired immune deficiency state, which would increase the risk of opportunistic infections and other complications during chemotherapy-induced lymphodepletion. If there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and\u002For infectious disease specialist\n* Hepatitis B or C seropositivity with evidence of ongoing liver damage, which would increase the likelihood of hepatic toxicities from the chemotherapy conditioning regimen and supportive treatments. If there is a positive result in the infectious disease testing that was not previously known, the patient will be referred to their primary physician and\u002For infectious disease specialist\n* Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol\n* A Tiffeneau-Pinelli index \\\u003C 70% of the predicted value. Subjects will be excluded if pulmonary function tests indicate they have insufficient pulmonary capability\n* Patients will be excluded if they have a history of clinically significant electrocardiography (ECG) abnormalities, symptoms of cardiac ischemia or arrhythmias and have a left ventricular ejection fraction (LVEF) \\\u003C 45% on a cardiac stress test (stress thallium, stress multigated acquisition scan (MUGA), dobutamine echocardiogram, or other stress test)\n* Patients with ECG results of any conduction delays (PR interval \\> 200 ms, corrected QT (QTC) \\> 480 ms), sinus bradycardia (resting heart rate \\\u003C 50 beats per minute), sinus tachycardia (HR \\> 120 beats per minute) will be evaluated by a cardiologist prior to starting the trial. Patients with any arrhythmias, including atrial fibrillation\u002Fatrial flutter, excessive ectopy (defined as \\> 20 ventricular premature complex \\[PVC\\]s per minute), ventricular tachycardia, 3rd degree heart block will be excluded from the study unless cleared by a cardiologist\n* Pregnancy or breast-feeding. Female patients must be surgically sterile or be postmenopausal for two years, or must agree to use effective contraception during the period of treatment and for 6 months afterwards. All female patients with reproductive potential must have a negative pregnancy test (serum\u002Furine) at screening and again within 14 days from starting the conditioning chemotherapy. The definition of effective contraception will be based on the judgment of the study investigators. Patients who are breastfeeding are not allowed on this study\n* A concomitant active malignancy that would be considered to interfere with the assessment of the primary or secondary endpoints of the study","75 Years",{"count":179,"type":19},18,[181],"PHASE1","This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene. The IL13Ralpha2 CAR gene is inserted into T cells with a virus called a lentivirus. The lentivirus allows cells to make the IL13Ralpha2 CAR protein. This CAR has been designed to bind to a protein on the surface of tumor cells called IL13Ralpha2. This study is being done to determine the dose at which the gene-modified immune cells are safe, how long the cells stay in the body, and if the cells are able to attack the cancer.",[184,185,186,187,188,189,190,191,192,193,107,25,194,195,196,197,198],"Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Recurrent Malignant Solid Neoplasm","Refractory Malignant Solid Neoplasm","Uveal Melanoma","Acral Melanoma","Neuroendocrine Tumors","Paraganglioma","Pancreatic Neuroendocrine Tumor","Thyroid Cancer","Breast Cancer","Lung Adenocarcinoma","Head and Neck Squamous Cell Carcinoma","2026-03-13",{"date":201,"type":83},"2026-03-17",{"date":203,"type":83},"2025-10-07",{"date":205,"type":19},"2026-10",{"name":207,"class":90},"Anusha Kalbasi",3,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":4,"enrollmentInfo":217,"targetDuration":4,"studyType":149,"phases":219,"briefSummary":220,"conditions":221,"keywords":229,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":233,"lastUpdatePostDateStruct":234,"startDateStruct":236,"completionDateStruct":238,"leadSponsor":240,"locationsCount":242},"100541703","phase-2-dostarlimab-for-locally-advanced-or-metastatic-cancer-non-colorectalnon-endometrial-with-tumor-dmmrmsi-100541703","NCT06333314","Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal\u002FNon-endometrial) With Tumor dMMR\u002FMSI","Dostarlimab as First-line Treatment for Patients With dMMR\u002FMSI (Non-colorectal\u002FNon-endometrial) Locally Advanced or Metastatic Cancer: a Randomized Phase 2 Trial (Cohort Pan-MSI ACSE) With Crossover in the Standard Arm at Progression","Pan-MSI-ACSE","Inclusion Criteria:\n\n1. Patient must have signed a written informed consent form prior any trial specific procedures. -\n2. 18 years or older patients.\n3. Documented locally advanced or metastatic disease with no previous systemic anti-cancer treatment in these settings and not suitable for complete surgical resection.\n4. Histologically proven, dMMR\u002FMSI-H solid tumors that are not colorectal or endometrial cancers and including one of the following: duodenum and small bowel adenocarcinoma, gastric and oeso-gastric junction adenocarcinoma with CPS\\\u003C5, pancreatic adenocarcinoma, ampulla of Vater adenocarcinoma, adrenocortical carcinoma, carcinoma of unknown primary site, neuroendocrine carcinoma (Grade 3) all primary, and soft tissue sarcoma except Gastro-Intestinal Stromal Tumor (GIST).\n5. If patient received adjuvant therapy for non-metastatic disease, this therapy should be completed more than 6 months before the diagnosis of metastatic or recurrent disease.\n6. Availability of minimum 1 block of tumor tissue or 20 slides (archival (\\\u003C2 years) or fresh biopsy specimen of primary and or metastasis) for centralized confirmation of MMR\u002FMSI status by IHC or NGS\u002FPCR, and for Translational Research.\n7. Patients with dMMR\u002FMSI tumor analyzed by IHC, PCR (for Gastric and OGJ adenocarcinoma, and duodenum and small bowel adenocarcinoma only), and\u002For NGS at the recruiting center should be confirmed by central review within 24h (every anonymized patient analysis reporting will be provided for central review). Patients should not be included in the study until the dMMR\u002FMSI status is confirmed by the review committee.\n\n   NB: In case of ambiguous result of IHC (lack of positive internal control, heterogeneous loss of MMR protein expression, ambiguous loss of only one protein including HMSH6 and PMS2), the MSI-H status will be assessed by PCR or NGS for gastric and OGJ adenocarcinoma, and duodenum and small bowel adenocarcinoma, and by NGS for other primary. Based on IHC and PCR or NGS results (NGS will be centrally performed in this case ), the sponsor will decide if inclusion is possible;\n8. Presence of at least one measurable lesion within 28 days before the start of treatment according to RECIST v1.1.\n9. Eastern Cooperative Oncology Group Performance status (ECOG PS) 0-1.\n10. Haematological status: absolute neutrophil count (ANC) ≥1.5 x 10⁹\u002FL; platelets ≥100 x 10⁹\u002FL; haemoglobin ≥9 g\u002FdL.\n11. Adequate renal function: serum creatinine level \\\u003C120 µM, or clearance \\>50 ml\u002Fmin (Modification of the Diet in Renal Disease \\[MDRD\\] or Cockcroft and Gault).\n12. Adequate liver function: serum bilirubin ≤1.5 x upper normal limit (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3.0 x ULN, unless liver metastases are present, in which case they must be ≤ 5× ULN.\n13. For patients not taking warfarin: International normalised ratio (INR) \\\u003C1.5 or prothrombin time (PT) \\\u003C1.5 x ULN and either partial thromboplastin time (PTT) or activated PTT (aPTT) \\\u003C1.5 x ULN. Participants taking warfarin may be included on a stable dose with a therapeutic INR \\\u003C3.5.\n14. Women of childbearing potential must have a negative serum pregnancy test performed within 72 hours before the date of randomization.\n15. Men, and women of childbearing potential must agree to use adequate contraception for the duration of trial participation and for 4 months after the last dose of dostarlimab (used in first line or at crossover) or for at least 6 months after the last administration of the chemotherapy agent(s) used in the control arm if no crossover with dostarlimab (according to the current version of the summary of product characteristics (SmPC) of each chemotherapy agent). Men must also agree to not donate sperm and women must agree to not donate oocytes during the specified period.\n16. Registration in a National Health Care System.\n17. Patient is willing and able to comply with scheduled visits, treatment schedule, laboratory tests, tumor biopsies, and other requirements of the study.\n\nExclusion Criteria:\n\n1. Colorectal and endometrial cancer and all primary tumor not listed in inclusion criterion #4.\n2. Previous exposure to anti-PD-1 or PD-L1 or anti-CTL-4 antibodies or treatment with immunotherapy.\n3. Previous exposure to any investigational drug within 4 weeks (6 weeks for monoclonal antibodies) before the first dose in the study.\n4. Previous exposure to any systemic anti-cancer therapy or radiation therapy for the cancer for which the patient is being enrolled.\n5. Active autoimmune disease: Active autoimmune disease requiring systemic treatment in the past 2 years (excluding replacement therapy) or any history of interstitial lung disease (patients with ancient auto-immune disease with stable endocrine oral substitution are eligible).\n6. Uncontrolled central nervous system metastases or carcinomatous meningitis or other concurrent illness or ongoing or active infections.\n7. Patients with HER2-positive gastric carcinoma.\n8. Other serious and uncontrolled non-malignant disease or is considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, non-infectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unstable spinal cord compression; superior vena cava syndrome; or any psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.\n9. Prior allogeneic bone marrow transplantation or prior solid organ transplantation.\n10. Has received treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 2 weeks prior to the first dose of adjuvant treatment or is required to receive systemic immunosuppressive medications during the study. Inhaled or topical steroids and adrenal replacement doses \\>10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease.\n\n    Note 1: Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled into the study after approval of the Medical Contact.\n\n    Note 2: patients are permitted the use of topical, ocular, intra-articular, intranasal, and inhalational corticosteroids (with minimal systemic absorption). Adrenal replacement steroid doses including doses \\>10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for prophylaxis (e.g., contrast dye allergy) or for treatment of non-autoimmune conditions (e.g., delayed-type hypersensitivity reaction caused by a contact allergen) is permitted.\n11. Other concomitant or previous malignancy other than the disease under study, except as noted below:\n\n    i. adequately treated in-situ carcinoma of the uterine cervix, ii. basal or squamous cell carcinoma of the skin, iii. cancer from which the patients was in complete remission for \\>2 years.\n12. Known Human Immunodeficiency Virus (HIV) infection.\n13. Received live vaccine within 14 days.\n14. Patient has documented presence of HBsAg \\[or HBcAb\\] at pre-inclusion visit or within 3 months prior to first dose of study intervention.\n\n    Participant has a positive hepatitis C virus (HCV) antibody test result at pre-inclusion visit or within 3 months prior to first dose of study intervention. Note: Participants with a positive HCV antibody test result due to prior resolved disease can be enrolled, only if a confirmatory negative HCV RNA test is obtained.\n\n    Participant has a positive HCV RNA test result at pre-inclusion visit or within 3 months prior to first dose of study intervention. Note: The HCV RNA test is optional and participants with negative HCV antibody test are not required to undergo HCV RNA testing as well\n15. Known prior severe hypersensitivity to investigational product or any component in its formulation.\n16. Pregnant or breast feeding women.\n17. Participation in another clinical trial within 30 days prior to the first study treatment administration or concomitantly with the trial.\n18. Presence of any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.\n19. Person deprived of their liberty or under protective custody or guardianship.\n\nPatient randomized to receive SOC (Arm B) may crossover to receive dostarlimab (Arm A) in case of documented progressive disease according to RECIST v1.1.\n\nInclusion and exclusion are the same for the crossover except for the inclusion criteria #3 and #4.\n\nThe criterion #3 for crossover is: Patient included in the protocol and randomized in the arm \"standard of care\" with documented progressive disease by RECIST v1.1 on standard of care (defined in the protocol).\n\nThe criterion #4 for crossover is: Previous exposure to chemotherapy for locally advanced or metastatic disease.",{"count":218,"type":19},120,[151],"The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)\u002Fmicrosatellite instability (MSI) non-resectable metastatic or locally advanced non-colorectal and non-endometrial cancers compared to the standard of care chemotherapy.\n\nAdult patients (aged ≥18 years) with histologically confirmed dMMR\u002FMSI duodenum and small bowel adenocarcinoma, gastric and oeso-gastric junction (OGJ) adenocarcinoma with combined positive score (CPS)\\\u003C5, pancreatic adenocarcinoma, ampulla of vater adenocarcinoma, adrenocortical carcinoma, carcinoma of unknown primary site, neuroendocrine carcinoma (Grade3) all primary, and soft tissue sarcoma (except Gastro-Intestinal Stromal Tumor) will be included in this study. They will be randomized and treated with either dostarlimab (experimental arm A), or chemotherapy (control arm B).\n\nPatients with documented disease progression following the first line chemotherapy (Arm B) may be eligible for crossover to be treated with dostarlimab, with the same schedule as arm A.",[222,223,25,224,225,226,227,228],"Pancreatic Adenocarcinoma","Ampulla of Vater Carcinoma","Neuroendocrine Carcinoma","Soft Tissue Sarcoma","Small Bowel Adenocarcinoma","Duodenum Adenocarcinoma","Gastric Adenocarcinoma",[230,231,232],"Immunotherapy","locally advanced or metastatic cancer","dMMR\u002FMSI (non-colorectal\u002Fnon-endometrial) cancer","2025-11-24",{"date":235,"type":83},"2025-12-02",{"date":237,"type":83},"2024-07-23",{"date":239,"type":19},"2030-09",{"name":241,"class":90},"UNICANCER",22,{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":4,"enrollmentInfo":249,"targetDuration":4,"studyType":149,"phases":250,"briefSummary":251,"conditions":252,"keywords":253,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":91},"100561256","phase-2-phase-ii-study-of-pd-1-antibody-combined-with-radiotherapy-in-recurrent-or-metastatic-adrenal-cortical-carcinoma-100561256","NCT06587802","Phase II Study of PD-1 Antibody Combined With Radiotherapy in Recurrent or Metastatic Adrenal Cortical Carcinoma","Inclusion Criteria:\n\n* Patients voluntarily participated in this study and signed informed consent;\n* Patients ≥18 years old;\n* ECOG score ≤2 points; Expected survival ≥6 months;\n* Pathological diagnosis of adrenal cortical carcinoma;\n* Inability or unwillingness to surgically resect recurrent or metastatic adrenal cortical cancer;\n* Adrenal cortical cancer has recurred or metastasized after receiving mitotan monotherapy, chemotherapy, or first-line regimens based on mitotan combined with cisplatin chemotherapy and has progressed, unable to tolerate or unwilling to accept the regimens;\n* Have at least one measurable lesion (RECIST1.1);\n* The main organs function well, and the laboratory examination indicators meet:\n* (1) Blood routine examination: Hemoglobin (HB) ≥90g\u002FL(5.6mmol\u002FL); Absolute neutrophil count (ANC) ≥1.5×109\u002FL; Total white blood cells ≥3.5×109\u002FL;\n\n  * Platelet (PLT) ≥80×109\u002FL; (2) Blood biochemical examination:\n\n    ① Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (liver metastasis\u002Fbone metastasis ≤5× ULN; Tumor bone metastasis ≤5ULN);\n\n    ② Serum total bilirubin (TBIL) ≤1.5×ULN;\n  * Serum creatinine Cr≤1.5×ULN or creatinine clearance ≥60ml\u002Fmin; Blood urea nitrogen (BUN)≤2.5× upper limit of normal value (ULN); ④ Albumin (ALB)≥30g\u002FL; (3) Blood coagulation test: Activated partial thromboplastin time (APTT), International Normalized ratio (INR), prothrombin time (PT) ≤1.5×ULN;\n* Women of childbearing age must confirm their non-pregnant status before enrollment, and all enrolled subjects (whether male or female) should take adequate contraceptive measures during the whole treatment period and 4 weeks after the end of treatment;\n* The subjects were willing to return to the hospital for follow-up and had good compliance.\n\nExclusion Criteria:\n\n* Receiving anti-tumor monoclonal antibodies or other investigational drugs before enrollment\n* Previously received other anti-PD-1 monoclonal antibody therapy or other drug therapy for PD-1 \u002F PD-L1\n* Radiotherapy has been used in the lesion area in the past\n* The lesion invades the intestinal duct, and there are contraindications to radiotherapy such as the risk of intestinal fistula caused by radiotherapy\n* Known allergic reaction to the active ingredient of PD-1 monoclonal antibody or any excipients\n* Have a medical condition that interferes with oral medication, including but not limited to difficulty swallowing, chronic diarrhea, or intestinal obstruction\n* Uncontrolled heart disease, such as heart failure with NYHA rating ≥2, unstable angina pectoris, history of myocardial infarction in the past year, and ventricular or supraventricular arrhythmias requiring treatment\n* Central nervous system metastasis with clinical symptoms, such as brain edema, requiring hormonal intervention, or brain metastasis progression;\n* Serious infections (CTCAE \\> Grade 2) occurred within 4 weeks prior to the first use of the study drug, such as severe pneumonia, bacteremia, and infection complications requiring hospitalization; Baseline chest imaging examination indicating active lung inflammation, signs and symptoms of infection within 2 weeks prior to first use of the study drug, or the need for oral or intravenous antibiotic treatment (excluding prophylactic antibiotic use)\n* Receive systemic sex hormone or other immunosuppressive therapy with an equivalent dose greater than 10mg prednisone\u002Fday within 4 weeks of signing the informed consent. Participants with a systemic sex hormone dose ≤10mg prednisone\u002Fday or inhaled\u002Ftopical corticosteroids could be enrolled\n* chronic hepatitis B active stage or active hepatitis C patients. Screening period hepatitis B surface antigen (HepatitsBSurfaceAntigen, HBsAg) or hepatitis b core antibody (HBcAb HepatitsBcoreAntibody,) or hepatitis c virus (HepatitisCVirus, HCV) antibody positive patients, Only through HepatitisBVirus (HBV) DNA detection (no more than 104 copies \u002FmL or 2000IU\u002FmL) and HCVRNA detection (no more than the lower limit of the assay) will he be included in the group test after the disease has been controlled. Hepatitis B virus carriers, hepatitis B whose disease has been controlled after drug treatment (no more than 104 copies \u002FmL of DNA or 2000IU\u002FmL), and cured hepatitis C patients can be enrolled\n* Significant vital organ dysfunction or uncontrollable comorbiditions, including but not limited to uncontrolled hypertension, decompensated cirrhosis, active peptic ulcer or bleeding disease\n* History of interstitial lung disease or non-infectious pneumonia; Participants with a history of drug-induced or radiation-induced non-infectious pneumonia without symptoms were admitted\n* Pregnant and lactating women and subjects of childbearing age who do not want to take contraceptive measures\n* Persons with mental illness, a history of alcohol or drug abuse, or inability to obtain informed consent\n* Other researchers have determined that participants are not suitable for this study, such as serious diseases, including mental illness, serious abnormal test results, and other social or family high-risk risk factors that require timely intervention\n* refuse or can not sign the informed consent.\n* Patients suspected of having other primary cancers; Patients with other primary malignancies within the 5 years prior to the study period (other than adequately treated cervical or skin cancer in situ, such as basal cell carcinoma, squamous cell carcinoma, or non-melanoma skin cancer)",{"count":179,"type":19},[151],"Adrenal cortical cancer is an extremely rare and highly aggressive malignancy with an incidence of 0.7-2 per million people · year and a 5-year overall survival rate of 15-44%, among which the 5-year survival rate of stage IV cortical cancer is only 13% and the prognosis is poor. Complete surgical resection is one of the most important ways to cure cortical cancer, but the surgical trauma is large, the complications are high, the postoperative recovery of patients is slow, and the tumor is difficult to achieve complete resection, and the postoperative recurrence and metastasis rate of patients is high, even for localized cortical cancer (stage I-III), the recurrence and metastasis rate is still close to 60%.\n\nRecurrent or metastatic cortical cancer is mainly treated with drugs. However, the current first-line drug therapy is only 22.3% effective, the tumor progression-free time is 5.6 months, and the serious adverse reaction rate is as high as 58.1%.\n\nThe effective rate of second-line treatment with chemotherapy and targeted drugs was less than 10%, and the tumor progression-free time was only 2.8 months.\n\nThe Phase II study of PD-1 monoclonal antibody in the treatment of cortical cancer showed that the treatment effective rate was 23%, and the tumor progression-free survival time was 2.1 months, which was comparable to the first-line regimen, and has been approved by the guidelines for advanced cortical cancer.\n\nRadiation therapy has high efficiency and local control rate, small side effects, and can inhibit tumor growth, relieve local pressure and pain. However, it only has a good effect on the irradiated site, and it is difficult to inhibit the progression of non-radiotherapy lesions and the generation of other new lesions.\n\nThe synergistic effect of immunotherapy combined with radiation therapy for metastatic stoves has been confirmed in many solid tumors such as kidney cancer, which can improve the local control rate of solid tumors and prolong the time of tumor progressive-free.\n\nIn the early stage, this research team applied PD-1 monoclonal antibody combined with radiotherapy to treat recurrent or metastatic adrenal cortical cancer in many cases after receiving first-line drug therapy regimen, which not only achieved local control of the radiotherapy focus, but also inhibited the progression of other metastases, and achieved longer disease control effect.",[25],[25,254,255],"radiotherapy","immunotherapy","2025-04-24",{"date":258,"type":83},"2025-04-29",{"date":260,"type":83},"2025-03-14",{"date":262,"type":19},"2027-03-14",{"name":264,"class":90},"Sun Yat-sen University",{"id":266,"slug":267,"hasResults":11,"nctId":268,"briefTitle":269,"officialTitle":270,"acronym":271,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":4,"enrollmentInfo":273,"targetDuration":4,"studyType":149,"phases":275,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":291},"100482548","phase-2-pembrolizumab-in-the-treatment-of-advanced-progressive-adrenocortical-carcinoma-100482548","NCT05563467","Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.","A Multicentre, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.","PEMBR-01","Inclusion Criteria:\n\n1. Signing the informed consent form to participate in the study\n2. Age over 18 years of age\n3. Histopathologically confirmed adrenocortical carcinoma\n4. The general condition of the patient was assessed according to the Eastern Cooperative Oncology Group (ECOG) scale \\\u003C2\n5. Measurable disease according to RECIST 1.1\n6. Confirmed progression according to RECIST 1.1 within the last 6 months in patients, who received at least one line chemotherapy according to the EDP or EDP-M\n7. Adequate function of the marrow and internal organs:\n\n   1. hemoglobin ≥ 9g%, neutrophils\\> 1500 \u002F mm3, platelets\\> 100 thousand \u002F mm3\n   2. bilirubin ≤ 2 x upper limit of normal (UNL), Alat, Aspat ≤ 3 x UNL (if livermetastases are present ≤ 5 x UNL)\n   3. creatinine clearance \\> 40 ml \u002F min\n   4. coagulation parameters: INR, PT, APTT \\\u003C1.5 x UNL (exception: patients undergoing anticoagulation therapy, where INR, PT, APTT remain within the therapeutic range recommended for the patient)\n8. For women of reproductive age : confirmed negative pregnancy test result, and the requirement of dual barrier contraception\n9. For men of reproductive age: the requirement of dual barrier contraception\n\nExclusion Criteria:\n\n1. Pre-treatment with an immune checkpoint inhibitor\n2. Any cancer therapy within the last 7 days (including mitotane)\n3. Persistent side effects of previous anti-cancer therapy in the\\> G1 stage or after surgical treatment (exception: alopecia)\n4. Immunosuppressive therapy present or conducted within the last 4 weeks\n5. Glucocorticoid therapy in a dose higher than the replacement dose (subject to the permitted use: inhaled or topical steroids, single administration of a steroid, e.g. in case of an allergic reaction to contrast, use of mineralocorticosteroids, steroids in the course of asthma or COPD)\n6. Previous allograft marrow or organ transplant\n7. Current or diagnosed in the last 2 years autoimmune disease with the exception of vitiligo, psoriasis not requiring systemic treatment, autoimmune disease of the thyroid gland\n8. Active or previously documented inflammatory disease of the large intestine\n9. Previous non-infectious pneumonia requiring steroid therapy\n10. Hepatitis B or C\n11. Active tuberculosis\n12. Current active infection requiring systemic treatment\n13. Symptomatic, untreated central nervous system (CNS) metastases (exception: patients with asymptomatic CNS metastases with prior surgery or radiotherapy and no history of intracranial bleeding)\n14. Circulatory failure NYHA ≥3\n15. Corrected QT interval\\> 500 ms\n16. Significant coexisting disease, including neoplastic, except for basal cell carcinoma of the skin, carcinoma in situ: prostate, cervix, breast\n17. Other significant comorbid disease that, in the investigator's opinion, would pose risks to the patient during therapy\n18. Pregnancy or breastfeeding\n19. Patients requiring dialysis\n20. The patient's inability to meet the requirements specified in the study protocol\n21. Vaccination with live vaccine within 3 months before starting treatment",{"count":274,"type":19},24,[151],"This study is a national, multicenter, interventional, phase II clinical trial on the use of pembrolizumab in advanced adrenocortical carcinoma, with confirmed progression within 6 months, following EDP or EDP-M ( etoposide, doxorubicin, cisplatin- mitotan) chemotherapy.\n\nAdrenocortical carcinoma is a very rare entity with poor prognosis and limited therapeutic options. Only radical surgical treatment of the early stages gives a chance for complete cure, however the risk of recurrence still remains high.\n\nThe results of clinical trials conducted outside Poland indicate a possible potential role of immunotherapy as a rescue treatment for adrenocortical carcinoma after standard therapeutic methods have been exhausted.\n\nThis study will evaluate the efficacy and tolerability of treatment with the immune checkpoint inhibitor pembrolizumab in locally advanced, non-operable or metastatic adrenocortical carcinoma after first line chemotherapy failure.\n\nThe study population will include adult patients (\\>18 years of age) with histopathologically confirmed adrenocortical carcinoma and confirmed progression according to RECIST 1.1 within 6 months, after first line chemotherapy with the EDP and EDP-M scheme. Patients must meet the inclusion criteria and must not meet the exclusion criteria described in the PEMBR-01 study protocol. The planned number of patients in the study is 24.\n\nThe treatment regimen will be based on Pembrolizumab administered intravenously in 3 weeks cycles at a dose of 200mg. For hormonally active tumors producing cortisol, it is hypothesized that the use of pembrolizumab in combination with effective steroidogenesis inhibition may enhance the effect of immunotherapy. In the study, metyrapone or ketoconazole will be used for this purpose.\n\nThe primary endpoint of the study will be the objective response rate to the treatment. The secondary endpoints will be progression-free survival, duration of response, overall survival, and treatment safety as well as the effect of therapy on patients' quality of life.\n\nConcurrently, the analysis of biomarkers in tumor tissue will be carried out, including tumour infiltrating lymphocytes, expression of programmed death ligand, microsatellite instability and tumour mutation burden.",[25],[279,280,281],"advanced adrenocortical carcinoma","progressive adrenocortical carcinoma","pembrolizumab","2025-03-28",{"date":284,"type":83},"2025-04-02",{"date":286,"type":83},"2023-01-31",{"date":288,"type":19},"2027-05-31",{"name":290,"class":90},"Maria Sklodowska-Curie National Research Institute of Oncology",4,{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":297,"acronym":298,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":149,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":91},"100509438","phase-2-evaluation-of-the-efficacy-of-addition-of-progesterone-to-standard-chemotherapy-in-adrenocortical-carcinoma-acc-100509438","NCT05913427","Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)","Prospective, Phase II Study to Evaluate the Efficacy of Addition of Progesterone to Standard Chemotherapy According to Etoposide-Doxorubicin-Cisplatin Scheme Plus Mitotane (EDP-M) in Patients With Advanced Adrenocortical Carcinoma (ACC)","PESETA","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of ACC\n* Locally advanced or metastatic disease not amenable to radical surgery resection\n* ECOG performance status 0-2\n* Effective contraception\n* Life expectancy \\> 3 months\n* Age \\> 18 years\n* Adequate bone marrow reserve (neutrophils \\>1,000\u002Fmm3 and\u002For platelets \\>80,000\u002Fmm3) and organ function (including renal, liver and cardiac function)\n* Be able to comply with the protocol procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* History of recent or active prior malignancy, except for cured non-melanoma skin cancer, cured in situ cervical carcinoma, breast ductal carcinoma in situ, or other treated malignancies where there has been no evidence of disease for at least 2 years\n* Renal insufficiency (estimated glomerular filtration rate \\[GFR\\]\\\u003C50 mL\u002Fmin\u002F1.73 m2) or significant liver insufficiency (serum bilirubin\\>2 times the upper normal range and\u002For serum alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\]\\>3 times the upper normal range). GFRs will be calculated according to the validated formula (MDRD)\n* Pregnancy or breast feeding\n* Congestive heart failure (ejection fraction\\\u003C45%)\n* Preexisting grade 2 peripheral neuropathy\n* Previous or current treatment with mitotane or other antineoplastic drugs for ACC\n* Previous radiotherapy for ACC\n* Any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration or that, in the judgment of the investigator, would make the patient inappropriate for entry into this study.",{"count":301,"type":19},80,[151],"This is a prospective randomized, double blind, placebo controlled phase II study planned in patients with advanced ACC. The study will be conducted at ASST Spedali Civili Hospital and University of Brescia in Brescia.",[25],"2024-07-31",{"date":307,"type":83},"2024-08-01",{"date":309,"type":83},"2022-06-08",{"date":311,"type":19},"2027-06-08",{"name":313,"class":90},"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":149,"phases":322,"briefSummary":323,"conditions":324,"keywords":4,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":91},"100386976","phase-2-phase-ii-study-for-combination-of-camrelizumab-and-apatinib-in-the-second-line-treatment-of-recurrent-or-metastatic-adrenocortical-carcinoma-100386976","NCT04318730","Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of adrenocortical carcinoma;\n2. Patients with metastatic or inoperable adrenocortical carcinoma that has progressed, metastasized, or recurred after first-line standard treatment (mitotane monotherapy, chemotherapy alone, mitotane combined chemotherapy);\n3. Aged \\>=18 years;\n4. Eastern Cooperative Oncology Group (ECOG) performance status 0-1;\n5. At least one measurable lesion, according to RECIST 1.1;\n6. Major organ functions within 28 days prior to treatment meet the following criteria(14 days without transfusion): HB≥80g\u002FL, ANC≥1.5x10\\^9\u002FL, PLT ≥80x10\\^9\u002FL; TBIL≤1.5 ULN, ALT and AST ≤2.5 ULN, if there exists hepatic metastases, ALT and AST ≤5 ULN, Cr ≤1.5 ULN or CCr ≥60ml\u002Fmin; INR or PT ≤1.5 ULN, APTT ≤1.5 ULN (if the patient is receiving anticoagulant therapy, PT and APTT should be within the expected treatment range); Cardiac Markers and BNP≤ULN；TSH≤ULN (If TSH is abnormal, T3 and T4 should be normal)\n7. Appropriate contraception should be used from the start of treatment to 120 days after the end of treatment;\n8. Have signed consent form.\n\nExclusion Criteria:\n\n1. Patients with another primary malignancy within 5 years prior to starting the study drug, except for cured in situ cervical carcinoma and cured non-melanoma skin cancer;\n2. Have central nervous system metastasis with symptoms and need hormonal intervention;\n3. Had received strong CYP3A4 inhibitors within one week prior to enrollment or received strong CYP3A4 inducers within two weeks prior to enrollment;\n4. Poor control of high blood pressure (SBP\\>140mmHg or DBP\\>90mmHg);\n5. Congestive heart failure of New York Heart Association (NYHA) Class III or IV;\n6. Thromboembolic events occurred within 1 year prior to enrollment;\n7. ECG QT interval \\>500ms;\n8. Previous systemic immunosuppressive therapy;\n9. Previous anti-PD-1, anti-PD-L1 antibody or anti- CTLA-4 antibody treatment;\n10. Received TKI treatment within 2 weeks prior to starting the study drug;\n11. Participate in clinical trials of other interventional drugs within 4 weeks prior to starting the study drug;\n12. Received systemic therapy with corticosteroids or other immunosuppressants within 2 weeks prior to starting the study drug;\n13. An anti-tumor vaccine or a live vaccine was given within 4 weeks prior to starting the study drug;\n14. Major surgery or severe trauma within 4 weeks prior to starting the study drug;\n15. Severe infections occurred within 4 weeks prior to starting the study drug;\n16. Have an active autoimmune disease or a history of autoimmune diseases;\n17. Have a history of immunodeficiency;\n18. Have an active tuberculosis infection;\n19. Have active hepatitis;\n20. Patients with symptoms of gastrointestinal bleeding or risk of bleeding;\n21. Active infection, or patients are pregnant or breast-feeding.",{"count":321,"type":19},21,[151],"Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor. According to the literature, the 5-year survival rate of ACC is 12%-47%. For patients with advanced ACC, mitotane alone or combined with traditional chemotherapy was the first-line standard treatment, but its progression-free survival was only about 1 year. However, for patients who fail the first-line treatment, there is a lack of effective treatment. For ACC patients who had failed first-line chemotherapy, a phase II clinical trial found that the objective response rate and the disease control rate of PD-1 inhibitor Keytruda were 14% and 64% respectively, and no grade 3 or 4 adverse events were observed. Anti-tumor angiogenic drugs combined with PD-1 inhibitors have shown impressive clinical data in many solid tumors. This study is aimed to evaluate the efficacy and safety of PD-1 inhibitor camrelizumab combined with apatinib in patients with recurrent or metastatic ACC after standard treatment failure, and to seek new treatment for this population.",[25],"2024-07-16",{"date":327,"type":83},"2024-07-17",{"date":329,"type":83},"2020-10-01",{"date":331,"type":19},"2025-04-01",{"name":333,"class":90},"West China Hospital",{"id":335,"slug":336,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":4,"eligibilityCriteria":340,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":4,"enrollmentInfo":341,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":343,"conditions":344,"keywords":355,"overallStatus":79,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":91},"100519938","surgical-treatment-of-adrenal-diseases--laparoscopic-vs-robotic-assisted-adrenalectomy-100519938","NCT06050057","Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy","Possibilities of Surgical Treatment of Adrenal Diseases: Comparison of Laparoscopic and Robotic-assisted Adrenalectomy-a Prospective Study","Inclusion Criteria:\n\n* Indicated adrenalectomy based on endocrinological and imaging examination.\n* Written consent to participate in the study.\n\nExclusion Criteria:\n\n* Simultaneous bilateral adrenalectomy.\n* Adrenal expansion \\> 12 cm.\n* Suspected malignant adrenal tumor with infiltrative growth or tumor venous thrombus according to imaging examination.",{"count":342,"type":19},100,"The goal of this multicenter, observational, analytic, randomized clinical trial is to analyze the laparoscopic and robot-assisted method in the surgical treatment of patients with adrenal diseases. The main question it aims to answer are:\n\n1. to find the superiority of one the the surgical method mentioned above\n2. to compare the quality of life in patients with adrenal mass before surgery and after laparoscopic or robotic-assisted adrenalectomy.",[345,346,347,348,349,350,351,107,105,352,25,353,354],"Adrenal Tumor","Adrenal Disease","Adrenal Mass","Adrenalectomy; Status","Adrenal Hyperplasia","Adrenal Gland Metastasis","Adrenal Cortex Diseases","Conn Adenoma","Adrenocortical Adenoma","Adrenocortical Tumor",[345,107,352,105,356,357,358],"Adrenalectomy","Laparoscopic surgery","da Vinci surgical system","2023-09-17",{"date":361,"type":83},"2023-09-22",{"date":363,"type":83},"2023-09-03",{"date":365,"type":19},"2026-06-30",{"name":367,"class":90},"University Hospital Olomouc"]